Loading...
•
Jun 30, 2024
Pulmonx Q2 2024 Earnings Report
Reported record worldwide revenue with increased U.S. revenue and a stable gross margin.
Key Takeaways
Pulmonx reported record worldwide revenue of $20.8 million for Q2 2024, a 21% increase year-over-year. U.S. revenue grew by 26% to $13.9 million. The company maintained a gross margin of 74%.
Achieved record worldwide revenue of $20.8 million, a 21% increase year-over-year.
U.S. revenue reached $13.9 million, a 26% increase year-over-year.
Gross margin remained stable at 74%.
Added 17 new Zephyr Valve U.S. treatment centers.
Revenue by Geographic Location
Forward Guidance
Pulmonx continues to expect revenue for the full year 2024 to be in the range of $81 million to $84 million. The Company continues to expect gross margin for the full year 2024 to fall within the range of 74% to 75%. Pulmonx continues to expect total operating expenses for the full year 2024 to fall within the range of $127 million to $129 million, inclusive of approximately $25 million of non-cash stock-based compensation.
Positive Outlook
- Revenue for the full year 2024 expected to be in the range of $81 million to $84 million.
- Gross margin for the full year 2024 expected to fall within the range of 74% to 75%.
- Commercial strategy demonstrating positive momentum.
- Expanding presence by opening new accounts.
- Preparing to launch new pilot programs to optimize patient workflows.
Challenges Ahead
- Total operating expenses for the full year 2024 expected to fall within the range of $127 million to $129 million.
- Includes approximately $25 million of non-cash stock-based compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...